Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)
Clinical trial NCT00431015 · COMPLETED
Trial details
- NCT number
- NCT00431015
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-01-01
- Primary completion
- 2011-08-01
- Enrollment
- 88
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.